Journal
PHARMACEUTICS
Volume 14, Issue 4, Pages -Publisher
MDPI
DOI: 10.3390/pharmaceutics14040689
Keywords
nanomaterials; bimodal therapy; topical skin treatment; magnetic nanoparticles; thin films; skin cancer; methacrylates
Categories
Funding
- Ministry for Education, Science, and Sport [C3330-19-952027]
- Slovenian Research Agency [P3-0036, P2-0084, J3-1762, J2-1725]
Ask authors/readers for more resources
Despite medical advances, skin-associated disorders continue to pose a unique challenge to physicians worldwide. Skin cancer is one of the most common forms of cancer, with over one million new cases reported annually. Surgical excision is currently the primary treatment, but alternatives such as topical treatment solutions are being explored. This study aimed to develop multilayer nanofilms for theranostic skin cancer treatment.
Despite medical advances, skin-associated disorders continue to pose a unique challenge to physicians worldwide. Skin cancer is one of the most common forms of cancer, with more than one million new cases reported each year. Currently, surgical excision is its primary treatment; however, this can be impractical or even contradictory in certain situations. An interesting potential alternative could lie in topical treatment solutions. The goal of our study was to develop novel multilayer nanofilms consisting of a combination of polyhydroxyethyl methacrylate (PHEMA), polyhydroxypropyl methacrylate (PHPMA), sodium deoxycholate (NaDOC) with incorporated superparamagnetic iron-platinum nanoparticles (FePt NPs), and the potent anticancer drug (5-fluorouracil), for theranostic skin cancer treatment. All multilayer systems were prepared by spin-coating and characterised by atomic force microscopy, infrared spectroscopy, and contact angle measurement. The magnetic properties of the incorporated FePt NPs were evaluated using magnetisation measurement, while their size was determined using transmission electron microscopy (TEM). Drug release performance was tested in vitro, and formulation safety was evaluated on human-skin-derived fibroblasts. Finally, the efficacy for skin cancer treatment was tested on our own basal-cell carcinoma cell line.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available